1.      Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med. 2006;100(8):1297-306.

2.      Ahmadizar F, Vijverberg SJ, Arets HG, et al. Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. Eur Respir J. 2016;48(4):1063-73.

3.      Bacharier LB, Covar RA, Haselkorn T, et al. Consistently very poorly controlled asthma is associated with greater activity and school impairment in children with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2019;7(1):314-6.

4.      Barker N, Thevasagayam R, Ugonna K, et al. Pediatric Dysfunctional Breathing: Proposed Components, Mechanisms, Diagnosis, and Management. Front Pediatr. 2020;8:379.

5.      Barker NJ, Jones M, O'Connell NE, et al. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in children. Cochrane Database Syst Rev. 2013;2013(12):Cd010376.

6.      Bergamini M, Kantar A, Cutrera R, Interest Group IPC. Analysis of the Literature on Chronic Cough in Children. Open Respir Med J. 2017;11:1-9.

7.      Bossley CJ, Fleming L, Ullmann N, et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413-20.e6.

8.      Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80.e3.

9.      Burgess SW, Sly PD, Morawska A, et al. Assessing adherence and factors associated with adherence in young children with asthma. Respirology. 2008;13(4):559-63.

10. Bush A, Saglani S, Fleming L. Severe asthma: looking beyond the amount of medication. Lancet Respir Med. 2017;5(11):844-6.

11. Bush A, Saglani S. Management of severe asthma in children. Lancet. 2010;376(9743):814-25.

12. Busse WW, Bleecker ER, FitzGerald JM, et al. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. J Allergy Clin Immunol. 2021;148(1):266-71.e2.

13. Cane RS, McKenzie SA. Parents' interpretations of children's respiratory symptoms on video. Arch Dis Child. 2001;84(1):31-4.

14. Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-96.

15. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308-11.

16. Chipps BE, Haselkorn T, Rosén K, et al. Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life. J Allergy Clin Immunol Pract. 2018;6(1):169-76.e2.

17. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.

18. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400.

19. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5).

20. Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-46.Lemanske RF, Jr., Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362(11):975-85.

21. Dunn NM, Katial RK, Hoyte FCL. Vocal cord dysfunction: a review. Asthma Res Pract. 2015;1:9.

22. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-41.

23. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011;127(2):382-9.e1-13.

24. Fleming L, Heaney L. Severe Asthma-Perspectives From Adult and Pediatric Pulmonology. Front Pediatr. 2019;7:389.

25. Fleming L, Koo M, Bossley CJ, et al. The utility of a multidomain assessment of steroid response for predicting clinical response to omalizumab. J Allergy Clin Immunol. 2016;138(1):292-4.

26. Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322-33.

27. Fleming L, Tsartsali L, Wilson N, et al. Longitudinal relationship between sputum eosinophils and exhaled nitric oxide in children with asthma. Am J Respir Crit Care Med. 2013;188(3):400-2.

28. Forno E, Weiner DJ, Mullen J, et al. Obesity and Airway Dysanapsis in Children with and without Asthma. Am J Respir Crit Care Med. 2017;195(3):314-23.

29. Gaillard EA, Kuehni CE, Turner S, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years. Eur Respir J. 2021;58(5).

30. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Fontana, WI 2025

31. Gupta L, Arigliani M, Cook J, et al. Choosing biologic therapy in children with severe asthma. Paediatr Respir Rev. 2025.

32. Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902.

33. Hirose K, Iwata A, Tamachi T, et al. Allergic airway inflammation: key players beyond the Th2 cell pathway. Immunol Rev. 2017;278(1):145-61.

34. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1).

35. Johansson H, Norlander K, Berglund L, et al. Prevalence of exercise-induced bronchoconstriction and exercise-induced laryngeal obstruction in a general adolescent population. Thorax. 2015;70(1):57-63.

36. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018;51(1).

37. Joseph-Bowen J, de Klerk NH, Firth MJ, et al. Lung function, bronchial responsiveness, and asthma in a community cohort of 6-year-old children. Am J Respir Crit Care Med. 2004;169(7):850-4.

38. Julien JY, Martin JG, Ernst P, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol. 2009;124(2):371-6.

39. Kechter A, Cho J, Miech RA, et al. Nicotine dependence symptoms in U.S. youth who use JUUL E-cigarettes. Drug Alcohol Depend. 2021;227:108941.

40. Kong DL, Qin Z, Shen H, et al. Association of Obstructive Sleep Apnea with Asthma: A Meta-Analysis. Sci Rep. 2017;7(1):4088.

41. Kopel LS, Phipatanakul W, Gaffin JM. Social disadvantage and asthma control in children. Paediatr Respir Rev. 2014;15(3):256-62; quiz 62-3.

42. Leggett JJ, Johnston BT, Mills M, et al. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest. 2005;127(4):1227-31.Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev. 2000;2003(2):Cd001496.

43. Lezmi G, Lejeune S, Pin I, et al. Factors Associated with Asthma Severity in Children: Data from the French COBRAPed Cohort. J Allergy Clin Immunol Pract. 2021;9(5):1969-79.

44. Licari A, Castagnoli R, Brambilla I, et al. Asthma Endotyping and Biomarkers in Childhood Asthma. Pediatr Allergy Immunol Pulmonol. 2018;31(2):44-55.

45. Lo DK, Beardsmore CS, Roland D, et al. Lung function and asthma control in school-age children managed in UK primary care: a cohort study. Thorax. 2020;75(2):101-7.

46. Manti S, Magri P, De Silvestri A, et al. Epidemiology of severe asthma in children: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(174).

47. Maspero JF, FitzGerald JM, Pavord ID, et al. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST.  Allergy. 76. Denmark2021. p. 2621-4.

48. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med. 2016;374(19):1842-52.Nordlund B, Melén E, Schultz ES, et al. Prevalence of severe childhood asthma according to the WHO. Respir Med. 2014;108(8):1234-7.

49. Menzies-Gow A, Colice G, Griffiths JM, et al. NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020;21(1):266.

50. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351(11):1068-80.

51. Okoniewski W, Lu KD, Forno E. Weight Loss for Children and Adults with Obesity and Asthma. A Systematic Review of Randomized Controlled Trials. Ann Am Thorac Soc. 2019;16(5):613-25.

52. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-207.

53. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350-400.

54. Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020;8(10):1032-44.

55. Pitrez PM, de Souza RG, Roncada C, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study. Pediatr Pulmonol. 2017;52(11):1408-13.Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9.

56. Prasad B, Nyenhuis SM, Imayama I, et al. Asthma and Obstructive Sleep Apnea Overlap: What Has the Evidence Taught Us? Am J Respir Crit Care Med. 2020;201(11):1345-57.

57. Sagel SD, Davis SD, Campisi P, et al. Update of respiratory tract disease in children with primary ciliary dyskinesia. Proc Am Thorac Soc. 2011;8(5):438-43.

58. Sandberg S, Paton JY, Ahola S, et al. The role of acute and chronic stress in asthma attacks in children. Lancet. 2000;356(9234):982-7.

59. Shields MD, F AL, Rivey MP, et al. Mobile direct observation of therapy (MDOT) - A rapid systematic review and pilot study in children with asthma. PLoS One. 2018;13(2):e0190031.

60. Shore SA, Fredberg JJ. Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol. 2005;115(5):925-7.

61. Smith JM, Smedley M, Kansra S, et al. Vaping induced lung injury in a 14-year-old girl. Pediatr Pulmonol. 2022;57(1):320-1.

62. Szefler SJ, Chmiel JF, Fitzpatrick AM, et al. Asthma across the ages: knowledge gaps in childhood asthma. J Allergy Clin Immunol. 2014;133(1):3-13; quiz 4.

63. Togias A, Gergen PJ, Hu JW, et al. Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes. J Allergy Clin Immunol. 2019;143(3):1003-11.e10.

64. Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390(10109):2247-55.

65. Yang CL, Simons E, Foty RG, et al. Misdiagnosis of asthma in schoolchildren. Pediatr Pulmonol. 2017;52(3):293-302.

66. Zaczeniuk M, Woicka-Kolejwa K, Stelmach W, et al. Methacholine challenge testing is superior to the exercise challenge for detecting asthma in children. Ann Allergy Asthma Immunol. 2015;115(6):481-4.